Multi-omics profiling establishes the polypharmacology of FDA Approved CDK4/6 inhibitors and the potential for differential clinical activity

The target profiles of many drugs are established early in their development and are not systematically revisited at the time of FDA approval. Thus, it is often unclear whether therapeutics with the same nominal targets but different chemical structures are functionally equivalent. In this paper we...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cell Chem Biol
Main Authors: Hafner, Marc, Mills, Caitlin Elizabeth, Subramanian, Kartik, Chen, Chen, Chung, Mirra, Boswell, Sarah Ann, Everley, Robert A., Liu, Changchang, Walmsley, Charlotte Sanden, Juric, Dejan, Sorger, Peter Karl
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6936329/
https://ncbi.nlm.nih.gov/pubmed/31178407
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.chembiol.2019.05.005
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados